Factors Related to Experiencing Pain in Patients Affected by Chronic Inflammatory Rheumatic Disease During the COVID-19 Pandemic

Tfarah El Joumani1, *, Hanan Rkain1, Fatima Zahrae Taik1, Kenza Hassouni2, Redouane Abouqal3, Sara Bahloul1, Nada Alami1, Latifa Tahiri1, Najia Hajjaj-Hassouni4, Fadoua Allali1
1 Department of Rheumatology B, El Ayachi Hospital, Faculty of Medicine and Pharmacy of Rabat, Mohammed V University, Rabat, Morocco
2 Ecole Internationale de Santé Publique, Université Mohammed VI des Sciences de la Santé, Casablanca, Morocco.
3 Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
4 International University of Rabat, Rabat, Morocco

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 260
Abstract HTML Views: 82
PDF Downloads: 185
ePub Downloads: 67
Total Views/Downloads: 594
Unique Statistics:

Full-Text HTML Views: 105
Abstract HTML Views: 62
PDF Downloads: 78
ePub Downloads: 51
Total Views/Downloads: 296

Creative Commons License
© 2022 El Joumani et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Rheumatology B, El Ayachi Hospital, Faculty of Medicine and Pharmacy of Rabat, Mohammed V University, Rabat, Morocco; Tel: 00212661090833; E-mail:



To evaluate the effects of the COVID-19 pandemic on the pain experienced by patients with CIRD and to analyze the associated factors.


A cross-sectional study was conducted amongst patients with rheumatic diseases using a questionnaire providing information on patients and disease characteristics.

Patients were asked to assess the level of pain they had experienced before and during the pandemic, using a single Visual Analogue Scale (VAS) ranging from 0 (no pain) to 10 (greatest pain).

Statistical Analysis System IBM SPSS Statistics V20.0.0 was used to analyze the study data.

We performed univariate multivariate analysis to search for any related factors to pain perception during the COVID-19 pandemic. Qualitative values were analyzed by the chi2 test. Quantitative values were analyzed by the Student test when the measures were normally distributed or by nonparametric tests (Mann–Whitney U) when the measures were not normally distributed (the Kolmogorov–Smirnov test was used to test normality).


Amongst the 350 patients who answered the questionnaire online, rheumatoid arthritis represented 62.3%, spondyloarthropathy 34.3%, and undifferentiated CIRD 3.4%. CIRD-related pain was reported by 79.1% of the patients

The level of pain, using the VAS of Pain, increased significantly during the COVID-19 pandemic (4,6 ± 2,8 and 5,4 ± 3 before and during the pandemic; p<0.001).

In the multivariate analysis, the factors causing the pain were: the negative impact of the coronavirus on accessing rheumatology care, the discontinuation of treatment, the disturbed sleep, and the negative psychological impact.


This survey showed that the COVID-19 pandemic had increased CIRD-related pain in patients. Factors influencing this pain should be considered to help patients cope with their chronic rheumatism in this global health crisis.

Keywords: COVID-19 pandemic, Pain, Chronic inflammatory rheumatic diseases, Treatment adherence, Follow-up, Impact.


The outbreak of coronavirus disease in 2019 (COVID-19) was caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, originating in Wuhan, China, where it emerged in late 2019 [1, 2]. The World Health Organization (WHO) declared a “global emergency” on January 30th, 2020. The disease then began spreading rapidly across the globe in February. The WHO declared COVID-19 a pandemic on March 11th [3].

The first known case of COVID-19 in Morocco was detected on March 2nd, 2020, and the first death attributed to the disease occurred on March 10th, 2020 [4].

This pandemic has important implications for patients with rheumatic diseases since most of them are undergoing various immunosuppressive therapies [5-7].

Top scientific organizations have issued recommendations to help rheumatologists care for patients with the rheumatic disease [8-11].

As part of the community of Moroccan rheumatologists, we are concerned about our patients, whether they have stopped their treatment and if they have a worse outcome on their health. We aim to assess the impact of COVID-19 on treatment adherence, to seeing their rheumatologist, and identify the factors related to experiencing pain during the pandemic.


This cross-sectional study was conducted from June 1st to June 30th, 2020 by the Rheumatology Department B at El Ayachi Hospital (national reference center managing rheumatic diseases), with the collaboration of the associations AMRAR (Moroccan Association for Research and Social Aid to Rheumatics) and AMP (Moroccan Association for the Fight Against Rheumatoid Arthritis).

The study included consecutive adult Moroccan patients (aged more than 18 years) suffering from CIRD: Rheumatoid Arthritis (RA), spondyloarthropathy, and undifferentiated CIRD. All patients included in this study had follow-up consultations with a rheumatologist.

The participants of this study were all patients following up in the El Ayachi Hospital (national reference center managing rheumatic diseases) and in the AMRAR and AMPS (Moroccan associations of patients with rheumatoid arthritis and spondyloarthritis) and were reachable by phone. Participants were called by phone, informing them about the purpose and process of the study.

The ethics committee approved the survey approved the survey at the University Mohammed V in Rabat (Faculty of Medicine and Pharmacy), which waived the requirement for informed consent and was conducted in conformity with the ethical principles of research. Answering the questionnaire was considered an agreement to use the responses and all data were analyzed anonymously.

The working group comprised a panel of experts, including three senior rheumatologists and two residents of rheumatology; an expert on infectious diseases and epide-

miology, and an expert in sociology.

We conducted a pilot test with the study committee members, who analyzed the validity of the questionnaire and identified issues that could lead to misunderstandings, and we made the necessary changes until we reached a general agreement. Two rheumatology residents collected the data through the online survey tool “google forms”. The duration of the interview was seven minutes.

2.1. Questionnaire

The questionnaire consists of binary or multiple-choice questions providing information in five sections:

(1) Patients and disease characteristics: age, gender, type of CIRD (RA, spondyloarthropathy, others), duration of disease, current treatment, and comorbidities.

(2) Impact of COVID-19 on seeing a rheumatologist: the impact of COVID-19 on seeing a rheumatologist was estimated through patients’ answers to four questions about difficulties in attending appointments, the nature of these difficulties and the use of telemedicine as an alternative.

(3) Treatment adherence during the pandemic: treatment adherence during the pandemic was assessed by questions about attitudes towards medical treatment (continuation or discontinuation), specification of the discontinued molecule and reasons for discontinuation.

(4) The psychological impact was evaluated by exploring the effects of the containment on negative emotions, quality of sleep, and its impact on psychological health.

(5) Pain caused by CIRD: patients were asked to assess the global pain they felt before and during the pandemic, using a single Visual Analogue Scale (VAS) ranging from 0 (no pain) to 10 (greatest pain).

2.2. Statistics

Statistical Analysis System IBM SPSS Statistics V20.0.0 was used to analyze the survey data.

The qualitative variables were expressed as frequencies. Quantitative values were expressed as mean and standard deviation (SD) or median (interquartile lower, upper).

We performed univariate and multivariate analyses to search for related factors and difficulties in seeing a rheumatologist and investigated pain perception during the pandemic. Qualitative values were analyzed by the chi2 test. Quantitative values were analyzed by the student test when the measures were normally distributed or by a nonparametric test (Mann–Whitney U) when the measures were not normally distributed (Kolmogorov–Smirnov test was used to test normality). Correlation analysis was used to analyze any association between quantitative values. P values of less than 0.05 were considered statistically significant.


3.1. Patients and Disease Characteristics

We received answers from 350 patients (68% females, mean age of 46,1 ± 14,4 years) suffering from CIRD (RA (62.3%), spondyloarthropathy (34.3%), and undifferentiated CIRD (3.4%) treated with conventional disease-modifying anti-rheumatic drugs (cDMARDs), and biologic disease-modifying anti-rheumatic drugs (bDMARDs) in respectively 67.4% and 30.6% of cases. Corticosteroids and nonsteroidal anti-inflammatories (NSAIDs) were taken by 39.1% and 33.7% of patients.

Table 1 summarizes the patients and disease characteristics.

3.2. Follow-up and Treatment Adherence

Difficulties in accessing rheumatology appointments were reported by 82.9% of the participants. The fear of going to a medical institution was noted in 62.8% of the cases, among other reasons (Fig. 1). Patients reported that they received rheumatism counseling by their rheumatologists in 65.1% of the cases.

Table 1. Patients and disease characteristics.
Patients and Disease Characteristics N=350.
Age (Years)* 46,1 ± 14,4 [14 - 89] -
Sex Female/Male (%) 68/32
- RA (%) 62.3
- Spondyloarthropathies (%) 34.3
- Undifferentiated CIRD (%) -3.4
Disease Duration (Years)* 10 (4 ; 15)
Current Treatment (s) (%) -
- NSAIDs 33.7
- Corticosteroids 39.1
- cDMARDs: 67.4
- bDMARDs: 30.6
Comorbidities (%) -
- Diabetes 10.3
- Cardiovasular diseases 21.1
- Pneumopathies 3.4
- Nephropathies 2.9
- Psychiatric diseases 5.4
Abbreviations: CIRD: Chronic Inflammatory Rheumatic Disease
RA: Rheumatoid arthritis
NSAIDs: non-steroidal anti-inflammatory drugs
cDMARDs: conventional Disease-modifying anti-rheumatic drugs
bDMARDs: biologic Disease-modifying anti-rheumatic drugs
*Expressed by medians and quartiles
Fig. (1). Causes of difficulties preventing access to a rheumatologist during the pandemic.

Table 2. Causes of treatment interruption in patients with CIRD.
Drugs Prevalence of Interruption Not Found in Pharmacies The Pharmacy Refuses to Give me the Treatment Without a Recent Prescription To Avoid the Decrease in Immunity and Therefore to Avoid Catching COVID-19 I Stopped the Follow-up, and so I Stopped the Treatment... Other reasons
NSAIDS (%) 54 0 27.8 74.1 44.4 27.8
Corticosteroids (%) 14 0 14.3 92.9 57.1 50
Methotrexate(%) 67 70.1 3 10.4 16.4 22.4
Sulfasalazine (%) 8 0 12.5 25 75 100
Synthetic antimalarial (%) 13 69.2 0 0 23.1 61.5
Leflunomide (%) 0 0 0 0 0 0
bDMARDs (%) 27 0 7.4 40.7 44.4 51.9
Abbreviations: NSAIDs: non-steroidal anti-inflammatory drugs
bDMARDs: biologic Disease-modifying anti-rheumatic drugs

According to 50% of the patients, the pandemic has affected their therapeutic compliance. Discontinued drugs were in decreasing order, as follows: synthetic antimalarials (68.4%), NSAIDs (45.8%), methotrexate (43.8%), bDMARDs (25.2%), Sulfasalazine (18.2%) and Corticosteroids (10.2%). Synthetic antimalarials and methotrexate were stopped because of unavailability (69.2% and 70.1%, respectively). Corticosteroids, NSAIDs, and bDMARDs were discontinued due to the fear of an increased risk of COVID-19 infection (92.9%, 74.1%, and 40.7%, respectively).

The causes of treatment interruption are summarized in Table 2.

3.3. The psychological impact of the pandemic

Patients reported that the pandemic negatively affected their mental health in 59.1% of cases. Sleep has been disrupted in 72.6% of patients during the pandemic.

Table 3 summarizes the negative emotions expressed during the containment.

3.4. Pain Experienced During the Pandemic

Pain caused by CIRD during the pandemic was reported by 79.1% of patients.

The levels of pain, using the VAS of pain, were, respectively, at 4,6 ± 2,8 and 5,4 ± 3 before and during the pandemic.

In multivariate analysis, the factors related to experiencing pain are treatment compliance, accessing rheumatology care, disturbed sleep, and the negative psychological impact of the pandemic.

Table 4 summarizes a multivariable analysis of these factors.

Table 3. Negative emotions during the containment.
Negative Emotions (%) - N = 350
Hopelessness - 23.7
Anxiety - 55.4
Fear - 29.7
Frustration - 22.9
Loneliness - 17.4
Anger - 22.6
Powerlessness - 24.3
Table 4. Multivariable analysis of factors associated with experiencing pain related to CIRD during the pandemic.
- P
Impact on accessing rheumatology care 0.05
Impact on therapeutic compliance <0.001
Disturbed sleep 0.001
Negative psychological impact 0.02
Supplementary data:
The link of the survey questionnaire:


This study illustrates the attitudes of Moroccan patients suffering from CIRD during the COVID-19 crisis. It shows the difficulties patients encountered in keeping a regular follow-ups with their rheumatologists, and the high prevalence of discontinued treatments. Experiencing pain during the pandemic would be determined by factors related to the patients and the interruption of monitoring their CIRD.

Most patients found it difficult to see their rheumatologist for many reasons: transportation difficulty, the fear of contracting the coronavirus on their way to the hospital, and an overall fear of catching COVID-19 at the hospital itself.

The discontinued treatments concerned symptomatic (nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids) and conventional and biological disease-modifying antirheumatic drugs. This is alarming and predicts more frequent CIRD outbreaks post-pandemic.

Unjustified discontinuation of long-term CIRD treatment may result in an increased risk of relapse and morbidity in patients with RA and spondyloarthropathy.

The data currently available of patients suffering from rheumatic diseases during the COVID-19 pandemic are reassuring and support the continuation of adequate treatment for better control of CIRD.

National and international recommendations of CIRD emphasize maintaining basic treatments and preventing infection by prioritizing social distancing and stopping immunosuppressants when contracting COVID-19 [8-11].

Aside from the discontinuation of methotrexate, which was mainly caused by the shortage and recurrent problems of availability of this molecule in Morocco, the reasons for discontinuing other drugs were dominated by the fear of patients contracting COVID-19 because of these medications. The shortage of methotrexate in Morocco is a problem that requires national mobilization to avoid overprescribing biological treatments in the context of limited economic resources.

Patients who reported stopping hydroxychloroquine due to the shortage of pharmacies were unaware of a special national initiative to help them acquire hydroxychloroquine.

This survey analyzed the factors associated with experiencing pain during the pandemic. There were also links between a higher level of pain and the difficulties in accessing appropriate care by rheumatologists and the interruption of CIRD medication.

These links confirmed by the analysis should be taken into consideration to improve the management of patients with CIRD.

After having identified the problems encountered by our patients suffering from CIRD, the team of doctors has developed videos in the Moroccan dialect intended for patients. The association’s rheumatologists took turns sending clear messages with concise content, adapting to the different categories of Moroccan patients. We stressed the importance of having patients suffering from CIRD return to routine care by scheduling their appointment as soon as possible with their corresponding rheumatologist. The objective is to assess the activity of rheumatism, adapt the drug treatments, and support the patients to undo any harm caused by the interruption of treatment during the pandemic.

Given the important links discovered between the fear of COVID-19 and the discontinuation of various drugs for rheumatic disease, we sent the patient association documents containing practical and updated medical information on COVID-19, responding to the patients’ concerns, which we have developed under the supervision of the Moroccan Society of Rheumatology (SMR). Furthermore, we asked our fellow psychiatrists to guide us on the appropriate steps to follow to support our patients and deal with the negative psychological consequences of COVID-19.


The pandemic has negatively impacted wellbeing, access to care, and treatment compliance in patients with chronic diseases [12-15].

This survey illustrated that the COVID-19 pandemic had exacerbated the experience of pain in CIRD patients. The factors implicated are the impact of the coronavirus on attending follow-up appointments and drug adherence. Factors influencing this pain should be considered to help patients cope with their rheumatism and this global health crisis.


VAS = Visual Analogue Scale
SARS-CoV-2 = Severe Acute Respiratory Syndrome Coronavirus 2
WHO = World Health Organization
SD = Standard Deviation
NSAIDs = Nonsteroidal Anti-inflammatory Drugs


The ethics committee approved the survey at the University Mohammed V in Rabat (Faculty of Medicine and Pharmacy).


No animals were used for studies that are the basis of this research. All the humans were used in accordance with the ethical standards of the committee responsible for human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2013 (


Waived the requirement for informed consent and was conducted in conformity with the ethical principles of research.


STROBE guidelines were used in this study.


The authors confirm that the data supporting the findings of this study are available within the manuscript.




The authors declare no conflict of interest, financial or otherwise.


We are grateful to all patients who participated in this survey and to our colleagues’ rheumatologists who made this survey possible.

Special thanks to all members of the Moroccan association for research and aid to rheumatics (Association Marocaine de Recherche et d'Aide aux Rhumatisants: AMRAR and the staff of the Moroccan association of patients with rheumatoid arthritis and spondylarthritis (Association Marocaine de Polyarthrite et de Spondyloarthrites) for their precious contribution to this study. Researching rheumatic diseases' impact is essential to develop more specific actions in rheumatology.


[1] Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020; 395(10223): 470-3.
[2] Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
[3] Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020; 91(1): 157-60.
[4] Maneesh P, El Alaoui A. How countries of south mitigate COVID-19: Models of Morocco and Kerala, India (April 3, 2020). Electronic Research Journal of Social Sciences and Humanities (II) 2020; 16-28.
[5] Ouédraogo DD, Tiendrébéogo WJS, Kaboré F, Ntsiba H. COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments. Clin Rheumatol 2020; 39(7): 2069-75.
[6] Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020; 79(5): 667-8.
[7] Schmeiser T, Broll M, Dormann A, et al. A cross sectional study on patients with inflammatory rheumatic diseases in terms of their compliance to their immunosuppressive medication during COVID-19 pandemic. Z Rheumatol 2020; 79(4): 379-84.
[8] Landewé RB, Machado PM, Kroon F, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis 2020.
[9] Schulze-Koops H, Specker C, Iking-Konert C, Holle J, Moosig F, Krueger K. Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic. Ann Rheum Dis 2020; 79(6): 840-2.
[10] Richez C, Flipo RM, Berenbaum F, et al. Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020. Joint Bone Spine 2020; S1297-319X(20): 30092-0.
[11] Mikuls TR, Johnson SR, Fraenkel L, et al. American college of rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 Pandemic: Version 1. Arthritis Rheumatol 2020; 72(8): 1241-51.
[12] Wolf MS, Serper M, Opsasnick L, et al. Awareness, attitudes, and actions related to COVID-19 among adults with chronic conditions at the onset of the US outbreak: A cross-sectional survey. Ann Intern Med 2020; 173(2): 100-9.
[13] Extance A. COVID-19 and long term conditions: What if you have cancer, diabetes, or chronic kidney disease? BMJ 2020; 368: m1174.
[14] Boettler T, Newsome PN, Mondelli MU, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Reports 2020; 2(3): 100113.
[15] Bhidayasiri R, Virameteekul S, Kim JM, Pal PK, Chung SJ. COVID-19: An early review of its global impact and considerations for Parkinson’s disease patient care. J Mov Disord 2020; 13(2): 105-14.